Navigation Links
Genetic Information Nondiscrimination Act clears Senate
Date:4/25/2008

The Senate passed the Genetic Information Nondiscrimination Act (GINA) on April 24, approving by unanimous consent an amended version of H.R. 493, which passed the House April 25, 2007 by a vote of 420-3. The House is expected to take up the measure again quickly before sending it to President Bush to sign the measure into law.

"After a very long wait, Americans can now be confident that their genetic information cannot be used by health insurers or employers in harmful or hurtful ways," says Kathy Hudson, director of the Genetics and Public Policy Center, established at Johns Hopkins University by The Pew Charitable Trusts. "Our challenge now is to make sure that doctors and patients are aware of these new protections so that fear of discrimination never again stands in the way of a decision to take a genetic test that could save a life."

The legislation, when signed, will fulfill the longstanding agreement among American citizens and politicians that protection from genetic discrimination should be clear and consistent, Hudson explains. Until now, individuals' genetic information has been protected only by a largely untested patchwork of state and federal regulations. Ninety-two percent of Americans are concerned that results of a genetic test could be used in ways that are harmful to the person.

Moreover, scientists can now in good conscience tell patients and research participants that their genetic information is protected against misuse by health insurers and employers. Linking gene variants to health outcomes often requires studies involving large numbers of people, but scientists report that potential subjects are deterred by the fear that their information could be used against them by employers or insurers. In a survey of more than 4000 people conducted earlier this year, for example, the Center found that when considering whether or not to participate in genetics research, 93 percent of respondents said it was important that it be illegal for insurers or employers to get my information.

In addition to impeding research that would help to bring about the much-heralded era of personalized medicine, the threat of discrimination affects individual patients who could benefit from genetic testing have sometimes foregone it out of concern over possible repercussions. When people opt not to be tested, they lose the opportunity to seek monitoring and preventive care to avoid conditions for which they are at higher risk. Passage of GINA means that Americans will no longer have to make the trade-off between genetic privacy and appropriate health care.

The Senate unanimously passed versions of GINA in 2003 and 2005, but in both years the bill stalled in committee in the House. Last year, however, the House passed the measure quickly and today, the Senate for a third time expressed its commitment to nondiscrimination.


'/>"/>

Contact: Rick Borchelt
rborche1@jhu.edu
202-663-5978
Genetics & Public Policy Center, Johns Hopkins University
Source:Eurekalert

Related medicine news :

1. USCCB Official Praises Senate Passage of Genetic Information Nondiscrimination Act
2. Coalition for 21st Century Medicine Congratulates U.S. Senate on Passage of Genetic Information Nondiscrimination Act
3. American College of Medical Genetics Applauds the Passage of the Genetic Information and Non-Discrimination Act of 2007 (GINA)
4. Tourette Syndrome Association Applauds the Passage of Genetic Information Nondiscrimination Act
5. AHIP Statement on Senate Passage of the Genetic Information Nondiscrimination Act
6. NIOXIN(R) Research Laboratories First to Market HairDX Genetic Test for Womens Hair Loss
7. Different mutations in single gene suggest Parkinsons is primarily an inherited genetic disorder
8. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
9. Researchers Identify New Genetic Links to Psoriasis
10. Navigenics(TM) Launches Health Compass Service, a Personal Genetic Assessment for Optimal Health
11. Know Your Personal Genetic Health to Age Better Now!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Event in New York City, with long-time partners The Paul Foundation, on November ...
(Date:12/4/2016)... Aliso Viejo, California (PRWEB) , ... December 04, ... ... self-animating lower third presets that have new attractive animation styles with unique displacement ... Pro3rd Displace features 30 pre-animated lower third designs. Choose from a variety of ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of ... Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, ... Jason brings extensive financial and operational leadership experience to Advanced Inc. He began his ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 /PRNewswire/ ... SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the ... by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) ... Novartis today announced that the data are being featured ... American Society of Hematology (ASH) Annual Meeting and ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: